Avricore Health Announces Stock Option Grant for 4,100,000 Common Shares
PorAinvest
sábado, 14 de junio de 2025, 1:09 am ET1 min de lectura
AVGR--
The options will vest quarterly and expire in five years, provided that the optionees continue to act as directors, officers, employees, or consultants of the company. This move is part of Avricore's strategy to incentivize and retain key personnel as it continues to develop and expand its flagship offering, HealthTab, a network of rapid testing devices in community pharmacies [1].
HealthTab combines best-in-class point-of-care technologies with a secure, cloud-based platform, enabling lab-accurate results from a few drops of blood and real-time data reporting. The system includes up to 23 key biomarkers for chronic disease management and has recently added capabilities for bacterial and viral tests, such as strep and COVID-19 [1].
Avricore Health Inc. aims to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. The HealthTab network model empowers pharmacists to play a greater role in primary care delivery while reducing costs and waiting times and providing multiple revenue streams [1].
The company's stock price has seen recent growth, with a 10% increase on June 13, 2025, closing at CAD $0.0550 [2].
References:
[1] https://www.streetinsider.com/Globe+Newswire/Avricore+Grants+Options/24937445.html
[2] https://ca.finance.yahoo.com/quote/AVCR.V/analysis/
AVRE--
Avricore Health Inc. has granted stock options for 4,100,000 common shares to its directors, officers, employees, and consultants at a price of CAD $0.05 per share. The options will vest quarterly and expire in 5 years. This move is part of Avricore's strategy to advance pharmacy practice and patient care through its flagship offering HealthTab, a network of rapid testing devices in community pharmacies.
Avricore Health Inc. (TSXV: AVCR), a pharmacy service innovator focused on advancing pharmacy practice and patient care, has announced the granting of stock options to its directors, officers, employees, and consultants. The company's board of directors approved the issuance of 4,100,000 common shares at an exercise price of CAD $0.05 per share [1].The options will vest quarterly and expire in five years, provided that the optionees continue to act as directors, officers, employees, or consultants of the company. This move is part of Avricore's strategy to incentivize and retain key personnel as it continues to develop and expand its flagship offering, HealthTab, a network of rapid testing devices in community pharmacies [1].
HealthTab combines best-in-class point-of-care technologies with a secure, cloud-based platform, enabling lab-accurate results from a few drops of blood and real-time data reporting. The system includes up to 23 key biomarkers for chronic disease management and has recently added capabilities for bacterial and viral tests, such as strep and COVID-19 [1].
Avricore Health Inc. aims to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. The HealthTab network model empowers pharmacists to play a greater role in primary care delivery while reducing costs and waiting times and providing multiple revenue streams [1].
The company's stock price has seen recent growth, with a 10% increase on June 13, 2025, closing at CAD $0.0550 [2].
References:
[1] https://www.streetinsider.com/Globe+Newswire/Avricore+Grants+Options/24937445.html
[2] https://ca.finance.yahoo.com/quote/AVCR.V/analysis/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios